Antimetastatic effects of electrochemotherapy and of histoincompatible interleukin-2-secreting cells in the murine Lewis lung tumor

Anti-Cancer Drugs

Volumn 9, Issue 6, 1998, Pages 551-556

  Orlowski, Stéphane ^a   An, Dongjian ^b   Belehradek Jr , Jean ^c   Mir, Lluis M ^c  

^a CNRS   (France)

^b Department of Oncology   (China)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

3LL tumor; Bleomycin; Electrochemotherapy; Interleukin 2; Lung metastases

Indexed keywords

BLEOMYCIN; INTERLEUKIN 2;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CANCER IMMUNOTHERAPY; CANCER THERAPY; ELECTROCHEMOTHERAPY; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 0031818006     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199807000-00006     Document Type: Article

References (27)

1. Mir LM, Orlowski S, Belehradek J Jr, Paoletti C. Electrochemotherapy: potentiation of antitumor effect of bleomycin by local electric pulses. Eur J Cancer 1991; 27: 68-72.
2. Belehradek J Jr, Orlowski S, Poddevin B, Paoletti C, Mir LM. Electrochemotherapy of spontaneous mammary tumors in mice. Eur J Cancer 1991; 27: 73-6.
3. Mir LM, Orlowski S, Belehradek J Jr, et al. Biomedical applications of electric pulses with special emphasis on antitumor electrochemotherapy. Bioelectrochem Bioenerg 1995; 38: 203-7.
4. Neumann E, Sowers AE, Jordan CA. Electroporation and electrofusion in cell biology. New York: Plenum Press 1989.
5. Orlowski S, Mir LM. Cell electropermeabilization: a new tool for biochemical and pharmacological studies. Biochim Biophys Acta 1993; 1154: 51-63.
6. Belehradek J Jr, Orlowski S, Ramirez LH, Pron G, Poddevin B, Mir LM. Electropermeabilization of cells in tissues assessed by the qualitative and quantitative electroloading of bleomycin. Biochim Biophys Acta 1994; 1190: 155-63.
7. Tounekti O, Pron G, Belehradek J Jr, Mir LM. Bleomycin, an apoptotis-mimetic drug that induces two types of cell death depending on the number of molecules internalized. Cancer Res 1993; 53: 5462-9.
8. Mir LM, Tounekti O, Orlowski S. Bleomycin: revival of an old drug. Gen Pharmacol 1996; 27: 745-8.
9. Ramirez LH, Orlowski S, An D, et al. Electrochemotherapy on liver tumors in rabbits. Br J Cancer 1998; in press.
10. Mir LM, Devauchelle P, Quintin-Colonna F, et al. First clinical trial of electrochemotherapy for the treatment of cat soft tissue sarcomas. Br J Cancer 1997; 76: 1617-22.
11. Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J Jr, Mir LM. Electrochemotherapy, a new antitumor treatment: first clinical phase I-II trial report. Cancer 1993; 72: 3694-700.
12. Domenge C, Orlowski S, Luboinski B, et al. Antitumor electrochemotherapy: new advances in the clinical protocols. Cancer 1996; 77: 956-63.
13. Mir LM, Glass LF, Serša G, et al. Effective treatment of cutaneous and subcutaneous malignant tumors by electrochemotherapy. Br J Cancer 1998; 77: in press.
14. Mir LM, Orlowski S, Poddevin B, Belehradek J Jr. Electrochemotherapy tumor treatment is improved by interleukin-2 stimulation of host's defenses. Eur Cytokine Netw 1992; 3: 331-4.
15. Roth C, Mir LM, Cressent M, et al. Inhibition of tumor growth by histoincompatible cells expressing interleukin-2. Int Immunol 1992; 4: 1429-36.
16. Mir LM, Roth C, Orlowski S, et al. Potentiation of the antitumoral effect of electrochemotherapy by an immunotherapy with allogeneic cells producing interleukin-2. C R Acad Sci (Paris) Sér III 1992; 314: 613-8.
17. Mir LM, Roth C, Orlowski S, et al. Systemic antitumor effects of electrochemotherapy combined with histoincompatible cells secreting interleukin-2. J Immunother 1995; 17: 30-8.
18. Sugiura K, Stock CC. Studies in a tumor spectrum. III The effect of phosphoramides on the growth of a variety of mouse and rat tumors. Cancer Res 1954; 15: 38-51.
19. Gorelik E, Segal S, Feldman M. Control of lung metastasis progression in mice: role of growth kinetics of 3LL Lewis lung carcinoma and host immune reactivity. J Natl Cancer Inst 1980; 65: 1257-64.
20. Ishikawa T, Ura M, Yamamoto T, Tanaka Y, Ishitsuka H. Selective inhibition of spontaneous pulmonary metastasis of Lewis lung carcinoma by 5′-deoxy-5-fluorouridine. Int J Cancer 1995; 61: 516-21.
21. Katz A, Shulman LM, Revel M, Feldman M, Eisenbach L. Combined therapy with IL-6 and inactivated tumor cells suppresses metastasis in mice bearing 3LL lung carcinomas. Int J Cancer 1993; 53: 812-8.
22. Ohe Y, Podack ER, Olsen KJ, et al. Combination effect of vaccination with IL2 and IL4 cDNA transfected cells on the induction of a therapeutic immune response against Lewis lung carcinoma cells. Int J Cancer 1993; 53: 432-7.
23. Tentori L, Leonetti C, Lozupone F, Bonmassar E. Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL). Cancer Immunol Immunother 1995; 41: 375-83.
24. Mastino A, Favalli C, Grelli S, et al. Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice. Int J Cancer 1992; 50: 493-9.
25. Heller R, Jaroszeski MJ, Leo-Messina J, et al. Treatment of B16 mouse melanoma with the combination of electropermeabilization and chemotherapy. Bioelectrochem Bioenerg 1995; 36: 83-7.
26. Šersa G, Cemazar M, Miklavcic D, Mir LM. Electrochemotherapy: variable antitumor effect on different tumor models. Bioelectrochem Bioenerg 1994; 35: 23-7.
27. Gorelik E, Fogel M, Feldman M, Segal S. Differences in resistance of metastatic tumor cells and cells from local tumor growth to cytotoxicity of natural killer cells. J Natl Cancer Inst 1979; 63: 1397-404.